Radiopharmaceutical Theranostics Market Size & Share Analysis - Growth Trends and Forecasts (2024 - 2029)

The Radiopharmaceutical Theranostics Market Report is Segmented by Type (Companion Diagnostic Radiopharmaceuticals and Targeted Therapeutic Radiopharmaceuticals), Radioisotopes (Technetium-99, Gallium-68, Iodine-131, Lutetium-177, Copper-67 and 64, and Other Radioisotopes), Source (Nuclear Reactors and Cyclotrons), Application (Oncology, Cardiology, Neurology, and Other Applications), End User (Hospitals, Diagnostic Imaging Centers, Research Institutes, and Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Report Offers Market Sizes and Forecasts in Terms of Value (USD) for the Above Segments.

Radiopharmaceutical Theranostics Market Size & Share Analysis - Growth Trends and Forecasts (2024 - 2029)

Radiopharmaceutical Theranostics Industry Overview

The radiopharmaceutical theranostics market is consolidated due to the presence of four to five major companies dominating it. Ongoing advancement efforts by major players such as Bayer AG, Cardinal Health, GE HealthCare, Jubilant Radiopharma, and Novartis AG for development, including the discovery of new tracers, ligands, and targeting agents, contribute to the market’s consolidation. These companies continually explore novel approaches, resulting in a diverse array of radiopharmaceutical products.

Radiopharmaceutical Theranostics Market Leaders

  1. Bayer AG

  2. Cardinal Health

  3. GE HealthCare

  4. Novartis AG

  5. Jubilant Pharmova Limited (Jubilant Radiopharma)

  6. *Disclaimer: Major Players sorted in no particular order
Radiopharmaceutical Theranostics Market Concentration

Radiopharmaceutical Theranostics Market Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?